A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma virus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN).

Trial Details

NCT ID
NCT06782555
Phase
PHASE1 / PHASE2
Sponsor
ImmunoGenesis
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Evofosfamide
  • Zalifrelimab
  • Balstilimab
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Histologically confirmed locally advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, or HPV-negative SCCHN for which no…
  • Appropriate to enter a clinical trial with a minimum estimated life expectancy of at least 3 months.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  • Measurable disease as defined by RECIST 1.1. Patients with castration-resistant prostate cancer can have measurable or evaluable disease per PCWG3 …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →